Page 248 - பல்கலைக்கழகம் ஆஃப் அலபாமா இல் பர்மிங்காம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

 E-Mail PHILADELPHIA A second study of the injectable anti-obesity medication, semaglutide, has confirmed the large weight losses reported in a study earlier this month, establishing the reliability and robustness of this new drug. With obesity affecting more than 40 percent of American adults, the findings could have a major impact on weight management in primary care and other settings. The study is published today in the Journal of the American Medical Association. The 68-week study was conducted at 41 sites in the United States from August 2018 to April 2020 and was designed to boost total weight loss with semaglutide by combining the medication with a more intensive diet and physical activity program than what was used in the STEP 1 trial, published online February 10th in the

United statesUniversity of pennsylvaniaPennsylvania hospitalNew jerseyThomas waddenW timothy garveyPenn medicine princeton healthLancaster behavioral health hospitalPerelman school of medicineUniversity of pennsylvania health systemUniversity of alabama at birminghamRuth perelman school of medicineHospital of the university pennsylvaniaNational institutes of healthDrug administrationDepartment of nutrition sciences